EcoDrugPlus

Cholecystokinin Receptor-Like

Ensembl ID : ENSAOCG00000009345
Gene Symbol: LOC111566607
2 Cross references
195 Possible Orthologues:

Cholesterol 24-Hydroxylase

Ensembl ID : ENSAOCG00000006267
Gene Symbol: LOC111578258
3 Cross references
259 Possible Orthologues:

Cholesteryl Ester Transfer Protein

Ensembl ID : ENSAOCG00000007506
Gene Symbol: CETP
3 Cross references
151 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSAOCG00000019843
Gene Symbol: CHRM2
3 Cross references
196 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSAOCG00000017005
Gene Symbol: CHRM2
3 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSAOCG00000022478
Gene Symbol: CHRM3
1 Cross references
188 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSAOCG00000010123
Gene Symbol: CHRM3
1 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSAOCG00000004306
Gene Symbol: CHRM4
4 Cross references
186 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSAOCG00000019784
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSAOCG00000005607
Gene Symbol: CHRNB2
3 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSAOCG00000019836
Gene Symbol: CHRNB4
3 Cross references
194 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSAOCG00000003412
Gene Symbol: CHRM5A
1 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).